A Double-Blind, Randomized, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of SLV354 After Oral Dose Administration in Healthy Adult Male Subjects.

Trial Profile

A Double-Blind, Randomized, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of SLV354 After Oral Dose Administration in Healthy Adult Male Subjects.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs SLV 354 (Primary)
  • Indications CNS disorders; Cognition disorders
  • Focus Adverse reactions
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 16 Aug 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 03 Jun 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top